# Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients

> **NCT02545361** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Kahr Medical**

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** KAHR-102

## Key facts

- **NCT ID:** NCT02545361
- **Lead sponsor:** Kahr Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04
- **Primary completion:** 2020-04
- **Final completion:** 2020-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Program de-prioritized
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02545361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02545361, "Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02545361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*